NCT05923541View on ClinicalTrials.gov

RD13-02 for Patients With r/r CD7+ T Cell Hematologic Malignancies

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

June 26, 2023

Primary Completion Date

August 31, 2024

Study Completion Date

August 31, 2024

Conditions
Hematologic Malignancies
Interventions
DRUG

RD13-02 cell infusion

Universal CAR-T cells targeting CD7

Trial Locations (1)

450003

Henan Cancer Hospital, Zhengzhou

All Listed Sponsors
collaborator

Nanjing Bioheng Biotech Co., Ltd.

INDUSTRY

lead

Henan Cancer Hospital

OTHER_GOV

NCT05923541 - RD13-02 for Patients With r/r CD7+ T Cell Hematologic Malignancies | Biotech Hunter | Biotech Hunter